Creo Medical Group (LON:CREO) Shares Up 24% – Still a Buy?

Creo Medical Group PLC (LON:CREO)’s stock price shot up 24% during mid-day trading on Friday . The stock traded as high as GBX 15.50 and last traded at GBX 14.11. 1,270,726 shares were traded during trading, an increase of 61% from the average session volume of 790,687 shares. The stock had previously closed at GBX 11.38.

Analysts Set New Price Targets

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Creo Medical Group in a research note on Thursday, April 16th.

Creo Medical Group Stock Performance

The company has a debt-to-equity ratio of 6.90, a current ratio of 5.28 and a quick ratio of 2.19. The company has a 50 day simple moving average of GBX 12.08 and a 200-day simple moving average of GBX 12.16. The stock has a market cap of £58.20 million, a P/E ratio of -14.11 and a beta of 1.62.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.